|
 CytRx Corporation (NASDAQ: CYTR)
CYTR , previously has initiated an open-label, single-center Phase 1b clinical trial to evaluate the pharmacokinetics of its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) in patients with metastatic solid tumors who have either relapsed or not responded to treatment with standard therapies. The data obtained from this study will identify the duration of exposure after infusion of aldoxorubicin as well as define the peak drug levels reached after treatment with two different doses of the drug. 
The single-center Phase 1b clinical trial will be conducted under the direction of Dr. Monica Mita at Cedars Sinai Medical Center in Los Angeles, California, and will evaluate the pharmacokinetics and safety of a new formulation of aldoxorubicin administered at doses of 230 mg/m2 and 350 mg/m2 every 21 days for up to 8 consecutive cycles CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, recently initiated both a Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and plans to meet with the FDA in the fourth quarter of 2012 to discuss a potential Phase 3 pivotal trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com. ****  Steris Corporation (NYSE: STE)
STE, and NeuroLogica Corp., designers and manufactures of portable imaging equipment, have formed a collaborative relationship to offer fully integrated, intraoperative surgical suites to healthcare systems. The goal of these joint efforts is to help healthcare providers expand their procedural capabilities, through improved workflow and cost-effective approaches for neurosurgical therapies. 
Steris Corporation (NYSE: STE) is a leading provider of infection prevention and surgical products and services, focused primarily on critical healthcare, pharmaceutical and research markets around the world. The Company supplies a broad array of equipment, consumable and service solutions that help assure productivity and quality. STERIS is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com. ****  Crown Equity Holdings Inc. (CRWE)
CRWE has launched a online service company CRWE Direct. CRWE Direct (www.crwedirect.com) is an online business-to-business marketplace for manufacturers and small to large businesses to purchase various types of merchandise. Manufacturers may start downloading their product immediately, free of charge during the next six months. Thereafter, there will be various annual fees. The listing process and image loading for both sites are user-friendly. Furthermore, CRWE Tube (www.crwetube.com ), a video sharing site of CRWE, allows billions of people around the world to upload, watch and share original videos. With online videos continuing to experience explosive, viral growth and the web rapidly moving from text to video, businesses will need to adapt to the shift in video distribution technology or quickly become irrelevant to their consumers who anticipate seeing video everywhere online. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com. **** To view recent article please visit http://crweselect.com/30867/stock-alerts/titan-machinery-inc-entered-agreement-to-acquire-toner%E2%80%99s-inc-titn-cytr/ *********** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crweselect.com/disclaimer).
Related Articles -
Crown Equity, CROWN EQUITY HLD, Crown Equity Holdings, CRWE, CRWE Direct, CRWE stock chart, CRWE Tube, crweselect, CYTR, CytRx, CytRx Corporation, Equ,
| 
